Hendrix, Craig W.

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., Tappero, J. W., Bukusi, E. A., Cohen, C. R., Katabira, E., et al. (2012) · New England Journal of Medicine

HIV/AIDS Research and InterventionsHIV/AIDS drug development and treatment

Cited by 3,256

Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.

Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., Henderson, F. L., Pathak, S. R., Soud, F. A., Chillag, K. L., et al. (2012) · New England Journal of Medicine

HIV/AIDS Research and InterventionsHIV/AIDS drug development and treatment

Cited by 1,996

Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.

Choopanya, K., Martin, M., Suntharasamai, P., Sangkum, U., Mock, P. A., Leethochawalit, M., Chiamwongpaet, S., Kitisin, P., Natrujirote, P., Kittimunkong, S., et al. (2013) · The Lancet

HIV/AIDS Research and InterventionsHIV, Drug Use, Sexual Risk

Cited by 1,463

Tenofovir-based preexposure prophylaxis for HIV infection among African women.

Marrazzo, J. M., Ramjee, G., Richardson, B. A., Gomez, K., Mgodi, N., Nair, G., Palanee, T., Nakabiito, C., van der Straten, A., Noguchi, L., et al. (2015) · New England Journal of Medicine

HIV/AIDS Research and InterventionsHIV/AIDS drug development and treatment

Cited by 1,296

Use of a vaginal ring containing dapivirine for HIV-1 prevention in women.

Baeten, J. M., Palanee-Phillips, T., Brown, E. R., Schwartz, K., Soto-Torres, L. E., Govender, V., Mgodi, N. M., Matovu Kiweewa, F., Nair, G., Mhlanga, F., et al. (2016) · New England Journal of Medicine

HIV/AIDS Research and InterventionsHIV/AIDS drug development and treatment

Cited by 772

Daily Oral Tenofovir and Emtricitabine–Tenofovir Preexposure Prophylaxis Reduces Herpes Simplex Virus Type 2 Acquisition Among Heterosexual HIV-1–Uninfected Men and Women: A Subgroup Analysis of a Randomized Trial

Celum, C., Morrow, R. A., Donnell, D., Hong, T., Hendrix, C. W., Thomas, K. K., Fife, K. H., Nakku-Joloba, E., Mujugira, A., Baeten, J. M., et al. (2014) · Annals of Internal Medicine

Herpesvirus Infections and TreatmentsHIV/AIDS Research and Interventions

Cited by 61

MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel

Cranston, R. D., Lama, J. R., Richardson, B. A., Carballo-Diéguez, A., Kunjara Na Ayudhya, R. P., Liu, K., Patterson, K. B., Leu, C.-S., Galaska, B., Jacobson, C. E., et al. (2017) · Clinical Infectious Diseases

HIV/AIDS Research and InterventionsHIV/AIDS drug development and treatment

Cited by 60

Candida infections: outcome and attributable ICU costs in critically ill patients

Pelz, R. K., Lipsett, P. A., Swoboda, S. M., Diener-West, M., Powe, N. R., Brower, R. G., Perl, T. M., Hammond, J. M., & Hendrix, C. W. (2000) · Journal of Intensive Care Medicine

Antifungal resistance and susceptibilityNosocomial Infections in ICU

Cited by 45

The Diagnostic Value of Fungal Surveillance Cultures in Critically Ill Patients

Pelz, R. K., Lipsett, P. A., Swoboda, S. M., Diener-West, M., Hammond, J. M., & Hendrix, C. W. (2000) · Surgical Infections

Antifungal resistance and susceptibilityNosocomial Infections in ICU

Cited by 36